Zenas BioPharma, Inc. (ZBIO) Stock Statistics & Valuation Metrics

Zenas BioPharma, Inc. has a market cap or net worth of $2.15B. The enterprise value is $1.35K.

Zenas BioPharma, Inc. has 65,176,720 shares outstanding. The number of shares has decreased by -2.65% in one year.

Zenas BioPharma, Inc.’s return on equity (ROE) is -1.56 and return on invested capital (ROIC) is -65.61%.

The current PE Ratio of Zenas BioPharma, Inc. is ―. Zenas BioPharma, Inc.’s PEG ratio is -0.03.

In the last 12 months, Zenas BioPharma, Inc. had revenue of 10.00M and earned -377.74M in profits. Earnings per share was -8.44.

In the last 12 months, operating cash flow was -225.97M and capital expenditures -2.00K, giving a free cash flow of -225.97M billion.

Zenas BioPharma, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Zenas BioPharma, Inc. upcoming earnings date is Nov 18, 2026, Before Open (Confirmed).

Zenas BioPharma, Inc. as a current ratio of 5.61, with Debt / Equity ratio of 157.67%

In the past 12 months, Zenas BioPharma, Inc. has paid -79.00K in taxes.

Zenas BioPharma, Inc. EV to EBITDA ratio is -4.30, with an EV/FCF ratio of -9.25.

Zenas BioPharma, Inc. has $643.13M in cash and marketable securities with $389.60M in debt, giving a net cash position of $253.53M billion.

Gross margin is -5972.60%, with operating margin of -2113.85%, and net profit margin of -3777.37%.

The average price target for Zenas BioPharma, Inc. is $43.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy